Y-mAbs Therapeutics (YMAB) - Operatsion rentabellik

Y-mAbs Corp (YMAB) kompaniyasining rasmiy ramzlari

Y-mAbs Therapeutics (YMAB) kam uchraydigan bolalar o'smalari uchun radioimmunoterapiyani ishlab chiqmoqda hamda Osiyo va Yevropa bo'ylab o'z mavjudligini kengaytirmoqda. Biroq, yagona mahsulotga bog'liqlik va global miqyosda kengayishning murakkabliklari daromadlilik risklarini yuzaga keltirmoqda. Operatsion samaradorlik tendentsiyasi ushbu jarayonlarni aniq namoyish etadi va joriy ko'rsatkich -31.20 darajasida mustahkamlandi. Biznes barqarorligi patent himoyasi va yangi indikatsiyalarning tartibga soluvchi organlar tomonidan tasdiqlanishiga asoslangan.

YMAB - Y-mAbs Therapeutics Inc Operatsion foyda normasi 04.07.2022 - 27.09.2025 oraligʻida

Y-mAbs Therapeutics - tahliliy kesimlar va asosiy koʻrsatkichlar (YMAB)

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning fundamental tahlili:YMAB, YmAbs
Y-mAbs Corp tayyor mahsulotlari

Y-mAbs Therapeutics (YMAB) Memorial Sloan Kettering bilan hamkorlikda bolalar onkologiyasi uchun antitanalarni ishlab chiqishga katta resurslar investitsiya qilmoqda. Operatsion foydaning tushumga nisbatini tahlil qilish orqali investor asosiy biznesdagi xarajatlarni boshqarish samaradorligini baholaydi. Ushbu metrika moliyaviy majburiyatlar hisobga olinishidan oldin, operatsion xarajatlar to'langanidan keyin qolgan foyda qismini ochib beradi. Ko'rsatkichning tendentsiyasi kompaniyaning xarajatlarning mutanosib bo'lmagan o'sishisiz ishlanmalarni kengaytirish qobiliyatini aks ettiradi, bu esa biznes baholashining uzoq muddatli fundamental barqarorligini belgilaydi.

Y-mAbs Therapeutics raqobatchilari tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|AURA (Aura Biosciences Inc) - Operatsion marja|Sotuvning operatsion rentabelligi candeltx.com CADL|Operatsion marja ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operatsion foyda normasi|Operatsion rentabellik Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operatsion rentabellik|TuHURA Biosciences Inc. - Operatsion marja|TARA - Operatsion marja|FATE (Fate Therapeutics) - Sotuvning operatsion marjasi|Sotuvning operatsion marjasi Aadi Bioscience, Inc.|Sotuvning operatsion marjasi TCRX|Operatsion rentabellik CSBR|Operatsion marja XBIT|Operatsion faoliyat rentabelligi CEL-SCI Corp.|Operatsion rentabellik ostherapies.com OSTX|RADX: Operatsion foyda bo'yicha sotuv rentabelligi|ARTV: Sotuvning operatsion marjasi|ANL (Adlai Nortye) - Operatsion foyda bo'yicha sotuv rentabelligi|Veru (VERU) - Operatsion rentabellik|Sotuvning operatsion marjasi Tempest Therapeutics Inc|Operatsion rentabellik Xilio Therapeutics|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja